January 17, 2020, Coralville, IA – In collaboration with colleagues at the University of Iowa and the Buck Institute for Research on Aging, Emmyon scientists Scott Ebert and Chris Adams published a new paper today describing a previously unknown mechanism of skeletal muscle atrophy.

The paper, entitled “Activating transcription factor 4 (ATF4) promotes skeletal muscle atrophy by forming a heterodimer with the transcriptional regulator C/EBPβ” was published in the Journal of Biological Chemistry. To view the paper, please click here.

January 2, 2020, Coralville, IA – Emmyon is pleased to announce that the US, Chinese and Israeli patent offices have issued several new patents for uses of ursolic acid and tomatidine.  These new patents significantly expand Emmyon’s IP coverage around ursolic acid and tomatidine.

December 1, 2019, Coralville, IA – Emmyon is delighted to announce that its Vice President of Chemistry, Dr. John Talley, has been named again (for the fifth year in a row) to the highly prestigious Power List of The Medicine Maker magazine.  The Medicine Maker Power List is comprised of the world’s 100 most influential people in drug discovery and development.

May 20, 2019, Coralville, IA – Emmyon is pleased to announce that seven leading scientists have joined our Scientific Advisory Board, bringing deep expertise and capabilities in drug development, clinical nutrition, skeletal muscle biology, metabolism, obesity, diabetes, aging and translational research. Our new SAB members are Drs. Sue Bodine, Daryl Granner, Peter Snyder, Blake Rasmussen, Bret Goodpaster, Teresa Zimmers, and Andrew Judge. Please see our Scientific Advisory Board page for further information.

January 11, 2019, Coralville, IA – Emmyon is pleased to announce that the Australian Patent Office has issued a new patent for the use of ursolic acid to increase muscle mass or reduce muscle atrophy, and the European Patent Office has issued a new patent for methods and compositions for treating muscle atrophy, increasing muscle mass and/or enhancing muscle formation using tomatidine.  These new patents, which are exclusively licensed to Emmyon from the University of Iowa Research Foundation, significantly expand Emmyon’s IP coverage around ursolic acid and tomatidine.  The patents’ lead inventor is Emmyon’s President, Chris Adams, MD, PhD.

December 16, 2018, Coralville, IA. – Emmyon is pleased to announce that Dr. John Talley has become the company’s Vice President of Chemistry. John has served as senior scientific advisor at Emmyon and led the company’s chemistry program since 2012.  He is one of the world’s most accomplished medicinal chemists and an inventor on more than 200 issued U.S. patents.  His inventions include the COX-2 specific inhibitors Celebrex®, Bextra®, Dynastat®, Deramaxx® and Trocoxil® and the hydroxyethyl sulfonamide class of inhibitors for the treatment of HIV/AIDS, marketed under the brand names of Agenerase® , Telzir® , and Prezista®.  The medicines invented by Dr. Talley have improved the health of millions of patients and generated over $40 billion in sales to date.  He received the prestigious PhRMA Discoverers Award in 2002 for the discovery of Celebrex®. For the past four years (2015-2018), Dr. Talley has been named to The Medicine Maker Power List, which recognizes the world’s most influential people in drug discovery and development.